Your browser is no longer supported. Please, upgrade your browser.
Settings
RNN Rexahn Pharmaceuticals, Inc. daily Stock Chart
RNN [NYSE]
Rexahn Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.06 Insider Own4.19% Shs Outstand230.54M Perf Week-2.57%
Market Cap38.48M Forward P/E- EPS next Y-0.10 Insider Trans0.00% Shs Float230.13M Perf Month17.54%
Income-11.60M PEG- EPS next Q-0.03 Inst Own18.60% Short Float1.00% Perf Quarter-35.23%
Sales- P/S- EPS this Y25.00% Inst Trans31.69% Short Ratio1.90 Perf Half Y-46.51%
Book/sh0.08 P/B2.09 EPS next Y-42.90% ROA-49.70% Target Price2.50 Perf Year-61.63%
Cash/sh0.09 P/C1.77 EPS next 5Y- ROE-67.40% 52W Range0.14 - 0.47 Perf YTD-54.02%
Dividend- P/FCF- EPS past 5Y15.00% ROI- 52W High-64.39% Beta-0.01
Dividend %- Quick Ratio12.70 Sales past 5Y- Gross Margin- 52W Low22.72% ATR0.01
Employees20 Current Ratio12.70 Sales Q/Q- Oper. Margin- RSI (14)42.74 Volatility8.20% 8.54%
OptionableNo Debt/Eq0.00 EPS Q/Q40.50% Profit Margin- Rel Volume0.56 Prev Close0.16
ShortableYes LT Debt/Eq0.00 EarningsNov 02 AMC Payout- Avg Volume1.21M Price0.17
Recom1.50 SMA20-1.34% SMA50-8.56% SMA200-36.53% Volume671,521 Change3.02%
Mar-20-15Initiated MLV & Co Buy $1.25
Dec-28-12Initiated Burrill Institutional Research Mkt Outperform $1
Jan-18-12Resumed Rodman & Renshaw Mkt Perform
Jun-16-11Resumed Brean Murray Buy $3
Dec-02-10Initiated Brean Murray Buy $3
Nov-25-16 04:04PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Shareholder Director Nominations
Nov-11-16 01:04PM  REXAHN PHARMACEUTICALS, INC. Financials
Nov-07-16 09:11AM  Rexahn reports 3Q loss
09:00AM  Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-16 04:18PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report +5.40%
Oct-31-16 09:00AM  Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 A Cancer Cell Specific Anticancer Agent GlobeNewswire
Oct-26-16 09:00AM  Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of Docetaxel for the Targeted Treatment of Solid Tumors GlobeNewswire
Oct-11-16 09:14PM  Rexahn Pharmaceuticals Nears 52-Week Low (RNN) at Investopedia
Oct-10-16 07:00AM  Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress GlobeNewswire
Oct-06-16 02:19PM  Rexahn Pharmaceuticals to Present Trial Data (RNN) at Investopedia
Oct-04-16 09:15AM  Key FDA Decisions and Trial Results Expected in October at 24/7 Wall St.
09:00AM  Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress GlobeNewswire
Sep-26-16 10:34AM  Rexahn Pharmaceuticals (RNN) Sees Hammer Chart Pattern: Time to Buy?
Sep-20-16 04:59PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Sep-14-16 09:08AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ -10.79%
09:00AM  Rexahn Announces $6 Million Registered Direct Offering GlobeNewswire
Sep-12-16 09:09AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:00AM  Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer GlobeNewswire
Sep-07-16 09:00AM  Rexahn Pharmaceuticals to Present at 18th Annual Rodman & Renshaw Global Investment Conference on September 12, 2016 GlobeNewswire
Aug-08-16 09:15AM  Rexahn reports 2Q loss
09:00AM  Rexahn Pharmaceuticals Reports Second Quarter 2016 Financial and Operational Results GlobeNewswire
Aug-05-16 04:11PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Jul-11-16 09:09AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:00AM  Rexahn Pharmaceuticals Strengthens Leadership Team GlobeNewswire
Jun-10-16 05:04PM  Rexahn Pharmaceuticals, Inc. :RNN-US: Earnings Analysis: Q1, 2016 By the Numbers : June 10, 2016
04:02PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to
Jun-06-16 09:02AM  Rexahn Pharmaceuticals Presents Clinical Data for Three Novel Targeted Oncology Programs at the 2016 American Society of Clinical Oncology Annual Meeting GlobeNewswire
May-23-16 09:37AM  Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting GlobeNewswire
May-19-16 09:20AM  Rexahn Drugs Deal a Death Blow to Solid Tumor Cancer
May-09-16 09:15AM  Rexahn reports 1Q loss
09:00AM  Rexahn Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Corporate Update GlobeNewswire
May-06-16 04:31PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Apr-28-16 09:00AM  ROTH Capital Partners' Joseph Pantginis Interviewed by The Life Sciences Report Marketwired
Apr-20-16 09:02AM  Rexahn Pharmaceuticals Presents Clinical Trial Results for Archexin® at the 2016 American Association for Cancer Research Annual Meeting GlobeNewswire
Apr-13-16 11:02AM  Rexahn Pharmaceuticals to Present at the 2016 American Association for Cancer Research Annual Meeting GlobeNewswire
Mar-29-16 09:19AM  Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral Anti-Cancer Therapeutic RX-3117 in the Treatment of Pancreatic and Bladder Cancer at noodls
09:00AM  Rexahn Pharmaceuticals Announces Initiation of Phase Ib/IIa Clinical Trial of Its Novel Oral Anti-Cancer Therapeutic RX-3117 in the Treatment of Pancreatic and Bladder Cancer GlobeNewswire
Mar-24-16 09:10AM  Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress at noodls -7.35%
09:00AM  Rexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress GlobeNewswire
Mar-14-16 09:51AM  Rexahn reports 4Q loss
09:00AM  Rexahn Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial Results GlobeNewswire
06:10AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report
Mar-02-16 05:51PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-29-16 02:00PM  13G Filing: Sabby Capital Opens Large Position in Rexahn Pharmaceuticals, Inc. (RNN) at Insider Monkey -5.69%
Feb-26-16 09:35AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ
09:00AM  Rexahn Announces $5 Million Registered Direct Offering GlobeNewswire
Feb-23-16 11:45AM  Oral is Better: Rexahn Astounds with New Cancer Data Accesswire +11.09%
Feb-08-16 09:00AM  Rexahn Pharmaceuticals Completes Stage 1 and Begins Enrollment in Stage 2 of Archexin® Phase IIa Clinical Trial in Metastatic Renal Cell Carcinoma GlobeNewswire -7.11%
Feb-01-16 09:31AM  Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 at noodls +5.59%
09:00AM  Rexahn Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference on Monday, February 8, 2016 GlobeNewswire
Jan-25-16 09:17AM  Rexahn Pharmaceuticals Announces Supinoxin Poster Presentations at the 2016 Gastrointestinal Cancers Symposium at noodls
09:00AM  Rexahn Pharmaceuticals Announces Supinoxin Poster Presentations at the 2016 Gastrointestinal Cancers Symposium GlobeNewswire
Jan-22-16 09:00AM  BioWatch News' Alan Leong Interviewed by The Life Sciences Report Marketwired +11.41%
Jan-12-16 09:00AM  New Preclinical Data for Supinoxin Show Oral Administration Produces Clinically Meaningful Tumor Growth Inhibition GlobeNewswire
Jan-11-16 09:00AM  Rexahn Pharmaceuticals Archexin® Shows Dose-Dependent Tumor Reduction in a Phase IIa Clinical Study GlobeNewswire
Jan-05-16 09:00AM  Rexahn Pharmaceuticals to Present at Biotech Showcase 2016 GlobeNewswire
Dec-18-15 09:00AM  BioNap Consulting's Jason Napodano Interviewed by The Life Sciences Report Marketwired -9.76%
Dec-14-15 09:00AM  Rexahn Pharmaceuticals Announces New Data for Supinoxin Showing Potent Tumor Growth Inhibition GlobeNewswire
Nov-23-15 03:07PM  Biotechs Under 20 Dollars Poised to Breakout Accesswire +5.41%
Nov-12-15 05:12PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Nov-11-15 09:00AM  Rexahn Pharmaceuticals to Present at the Stifel 2015 Healthcare Conference on November 18, 2015 GlobeNewswire
Nov-06-15 09:09AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -11.69%
09:00AM  Rexahn Announces $7.0 Million Registered Direct Offering GlobeNewswire
Nov-05-15 09:07AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
09:00AM  Rexahn Pharmaceuticals Reports Interim Clinical Data for Archexin® at the 14th International Kidney Cancer Symposium GlobeNewswire
Nov-04-15 07:47AM  4 Stocks Under $10 Making Big Up Moves on Big Volume at TheStreet
Nov-03-15 09:37AM  Rexahn reports 3Q loss +8.38%
09:00AM  Rexahn Pharmaceuticals Reports Third Quarter 2015 Financial Results and Provides Corporate Update GlobeNewswire
Nov-02-15 04:46PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Oct-26-15 09:13AM  Rexahn Pharmaceuticals Receives U.S. Patent for RX-3117 Anti-Cancer Program GlobeNewswire
Oct-14-15 09:00AM  Rexahn Pharmaceuticals to Present at the 14th Annual BIO Investor Forum GlobeNewswire
Sep-30-15 09:00AM  Rexahn's Human Data Confirms Anti-Cancer Advantage Accesswire
Sep-28-15 09:13AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -13.11%
09:00AM  Rexahn Pharmaceuticals Presents Preliminary Clinical Data for Supinoxin(TM) and RX-3117 Oncology Programs at the European Cancer Congress 2015 GlobeNewswire
Sep-25-15 09:00AM  Rexahn Pharmaceuticals to Present Preliminary Clinical Data at the European Cancer Congress 2015 GlobeNewswire
Sep-23-15 09:00AM  Rexahn Pharmaceuticals to Present at the 15th Annual Biotech in Europe Investor Forum GlobeNewswire
Sep-10-15 09:01AM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Sep-08-15 09:01AM  Rexahn Pharmaceuticals to Present at the Biopharm America(TM) 2015 Conference in Boston GlobeNewswire
Aug-31-15 09:00AM  Rexahn Pharmaceuticals to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 10, 2015 GlobeNewswire
Aug-10-15 09:24AM  Rexahn reports 2Q loss
09:00AM  Rexahn Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-15 08:13PM  10-Q for Rexahn Pharmaceuticals, Inc. at Company Spotlight
Aug-07-15 06:16PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
Jul-17-15 04:13PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
Jul-14-15 09:02AM  Rexahn Pharmaceuticals Awarded Patent in Japan for Novel Targeted Cancer Drug Delivery Platform GlobeNewswire +10.91%
Jun-22-15 09:00AM  Rexahn Announces the Appointment of Peter Brandt as Chairman of the Board GlobeNewswire
Jun-09-15 09:00AM  Data on Rexahns RX-3117 in Non-Small Cell Lung Cancer Presented at 16th International Symposium of the Purine and Pyrimidine Society GlobeNewswire
Jun-08-15 09:00AM  National Cancer Institute Accepts Rexahn's RX-21101 for Its Nanotechnology Characterization Laboratory's Preclinical Characterization Program GlobeNewswire
Jun-05-15 04:20PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-29-15 08:51AM  5 Stocks Under $10 Ready to Spike Higher at TheStreet
May-28-15 09:00AM  Strong Data on Rexahn's Non-Toxic Targeted Therapy Revealed at Top Cancer Meetings Accesswire
May-13-15 05:01PM  Rexahn Announces Poster Presentations at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-11-15 09:00AM  Rexahn Pharmaceuticals Reports First Quarter 2015 Financial Results and Pipeline Update GlobeNewswire
May-10-15 08:11PM  10-Q for Rexahn Pharmaceuticals, Inc. at Company Spotlight
May-08-15 04:49PM  REXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report
May-04-15 08:12PM  10-K for Rexahn Pharmaceuticals, Inc. at Company Spotlight
Apr-21-15 09:12AM  New Data Show Rexahn's Supinoxin(TM) Decreases the Migration of Human Triple Negative Breast Cancer Cells in a Metastatic Cancer Model at noodls
09:00AM  New Data Show Rexahn's Supinoxin(TM) Decreases the Migration of Human Triple Negative Breast Cancer Cells in a Metastatic Cancer Model GlobeNewswire
Apr-20-15 09:40AM  Rexahn Identifies RX-3117 Biomarker & Presents Data at the 2015 American Association for Cancer Research Annual Meeting at noodls
09:00AM  Rexahn Identifies RX-3117 Biomarker & Presents Data at the 2015 American Association for Cancer Research Annual Meeting GlobeNewswire
Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The company's clinical stage oncology candidates include Archexin that completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; RX-3117, which is in Phase Ib clinical trial for the treatment of patients with solid tumors; and Supinoxin that is in Phase I clinical trial for patients with solid tumors. It is also involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is based in Rockville, Maryland.